Skip to content

Study · Animal study (in vivo) · rat · 2007

3 results

Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist.

Princivalle M, Broqua P, White R, Meyer J, Mayer G, Elliott L, Bjarnason K, Haigh R, Yea C

The Journal of pharmacology and experimental therapeutics19 Dec 2006Cited by 37 (Europe PMC)

PMID17179469 (opens in a new tab)DOI10.1124/jpet.106.112326 (opens in a new tab)PepBankPUB-17179469
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats, degarelix produced fast and sustained suppression of the pituitary gonadal axis.

    In plain wordsIn rats, degarelix produced fast and sustained suppression of the pituitary gonadal axis.

    Peptide
    Degarelix
    Outcome
    DecreasePituitary gonadal axis suppression
    Study

    ratn: not reported in source

    Dunning R-3327H carcinoma in Copenhagen rats
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We report in this study that degarelix produces a fast and sustained suppression of the pituitary gonadal axis in rats
    2 context sentences
    Summary · context
    One of the few animal models of prostate adenocarcinoma is the Dunning R-3327H rat carcinoma transplanted into Copenhagen rats.
    Summary · context
    First, degarelix as been compared with d-Trp(6)-luteinizing hormone-releasing hormone and surgical castration on a short-term study (2 months); and second, degarelix has been compared with leuprolide and surgical castration on a long-term study (12 months).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats with Dunning carcinoma, degarelix inhibited tumor growth at least comparably to surgical castration in the short-term study.

    In plain wordsIn rats with Dunning carcinoma, degarelix inhibited tumor growth at least comparably to surgical castration in the short-term study.

    Peptide
    Degarelix
    Outcome
    Direction not reportedTumor growth inhibition in short-term study
    Study

    ratn: not reported in source

    Dunning R-3327H carcinoma in Copenhagen rats
    Comparator
    surgical castration
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · 2 monthsAs given in this study (rat).

    Source sentences

    Summary
    In both studies, degarelix demonstrated a sustained inhibition of tumor growth at least comparable with surgical castration.
    2 context sentences
    Summary · context
    First, degarelix as been compared with d-Trp(6)-luteinizing hormone-releasing hormone and surgical castration on a short-term study (2 months); and second, degarelix has been compared with leuprolide and surgical castration on a long-term study (12 months).
    Summary · context
    One of the few animal models of prostate adenocarcinoma is the Dunning R-3327H rat carcinoma transplanted into Copenhagen rats.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats with Dunning carcinoma, degarelix inhibited tumor growth at least comparably to surgical castration in the long-term study.

    In plain wordsIn rats with Dunning carcinoma, degarelix inhibited tumor growth at least comparably to surgical castration in the long-term study.

    Peptide
    Degarelix
    Outcome
    Direction not reportedTumor growth inhibition in long-term study
    Study

    ratn: not reported in source

    Dunning R-3327H carcinoma in Copenhagen rats
    Comparator
    surgical castration
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · 12 monthsAs given in this study (rat).

    Source sentences

    Summary
    In both studies, degarelix demonstrated a sustained inhibition of tumor growth at least comparable with surgical castration.
    2 context sentences
    Summary · context
    First, degarelix as been compared with d-Trp(6)-luteinizing hormone-releasing hormone and surgical castration on a short-term study (2 months); and second, degarelix has been compared with leuprolide and surgical castration on a long-term study (12 months).
    Summary · context
    One of the few animal models of prostate adenocarcinoma is the Dunning R-3327H rat carcinoma transplanted into Copenhagen rats.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 2

    27 Oct 2026, 16:37 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.